<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720352</url>
  </required_header>
  <id_info>
    <org_study_id>VI-17-06</org_study_id>
    <nct_id>NCT04720352</nct_id>
  </id_info>
  <brief_title>Prospective US Radiofrequency SUI Trial</brief_title>
  <acronym>PURSUIT</acronym>
  <official_title>PURSUIT: Prospective US Radiofrequency SUI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viveve Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viveve Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized,&#xD;
      sham controlled, double blind study in premenopausal women with stress urinary incontinence.&#xD;
      The study will be conducted in 390 subjects, randomized 2:1 with active or sham treatment.&#xD;
      Study duration is 12 months post treatment. The primary objective is to evaluate the efficacy&#xD;
      of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary&#xD;
      incontinence (SUI), assessed using the 1-hour Pad Weight Test for up to 12 months&#xD;
      post-treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized,&#xD;
      sham controlled, double blind study in premenopausal women with stress urinary incontinence.&#xD;
      The study will be conducted in 390 subjects, randomized 2:1 with active or sham treatment.&#xD;
      Study duration is 12 months post treatment. The primary objective is to evaluate the efficacy&#xD;
      of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary&#xD;
      incontinence (SUI), assessed using the 1-hour Pad Weight Test for up to 12 months&#xD;
      post-treatment. Secondary endpoints include:&#xD;
&#xD;
        -  Percent of subjects who are responders in the 1-hour Pad Weight Test at 3- and 6-months&#xD;
           post-treatment.&#xD;
&#xD;
        -  Change from Baseline (CFB) to 3, 6- and 12-months post-treatment in the number of&#xD;
           incontinence episodes as assessed by the 3-day bladder voiding diary.&#xD;
&#xD;
        -  Percent of subjects with no incontinence episodes at 3, 6- and 12-months post-treatment&#xD;
           as assessed by the 3-day bladder voiding diary.&#xD;
&#xD;
        -  CFB to 3, 6, 9- and 12-months post-treatment in the I-QOL, ICIQ-UI-SF, PGI-I and MESA&#xD;
           questionnaires.&#xD;
&#xD;
        -  Percent CFB to 3, 6- and 12-months post-treatment in the 1-hour Pad Weight Test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-hour pad weight test</measure>
    <time_frame>12 months</time_frame>
    <description>Standard test of incontinence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-day diary</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Voiding diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-hour pad weight test</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Standard test of incontinence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I)</measure>
    <time_frame>3, 6, 9, and 12 months</time_frame>
    <description>Single question patient assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical, Epidemiologic, and Social aspects of Aging (MESA) questionnaire</measure>
    <time_frame>3, 6, 9, and 12 months</time_frame>
    <description>Questionnaire for stress and urge incontinence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Consultation on Incontinence Modular Questionnaire-Urinary Incontinence Short Form (ICIQ-UI-SF)</measure>
    <time_frame>3, 6, 9, and 12 months</time_frame>
    <description>Incontinence severity, frequency QOL questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence Quality of Life (I-QOL)</measure>
    <time_frame>3, 6, 9, and 12 months</time_frame>
    <description>QOL assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Urinary Incontinence, Stress</condition>
  <arm_group>
    <arm_group_label>Sham Comparator</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham delivers non therapeutic levels of radiofrequency and cryogen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active arm delivers radiofrequency and cryogen</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active treatment</intervention_name>
    <description>Active treatment delivers radiofrequency and cryogen</description>
    <arm_group_label>Active Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham delivers non therapeutic levels of radiofrequency and cryogen</description>
    <arm_group_label>Sham Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        I.1 Able to understand and has voluntarily signed and dated the most current informed&#xD;
        consent form (ICF) prior to initiation of any screening or study-specific procedures.&#xD;
&#xD;
        I.2 Willing to comply with study requirements and instructions.&#xD;
&#xD;
        I.3 Symptoms and diagnosis of stress urinary incontinence as determined by the following:&#xD;
&#xD;
          1. If there are mixed symptoms there must be a predominant stress component as determined&#xD;
             by the 3-day diary results and MESA questionnaire&#xD;
&#xD;
          2. Patient-reported or history of SUI symptoms for &gt; 6 months prior to screening.&#xD;
&#xD;
          3. Positive Bladder Stress Test at the Baseline Visit.&#xD;
&#xD;
          4. Positive Q-tip test at the Baseline Visit (the observation of an angle that exceeds 30&#xD;
             degrees from horizontal in the opinion of the investigator or designee to denote&#xD;
             hypermobility).&#xD;
&#xD;
          5. 1-hour pad weight at the Baseline Visit with a &gt;10 and &lt;50 g net increase from the&#xD;
             pre-test pad weight.&#xD;
&#xD;
          6. Subjects must complete 3 days in the 3-day voiding diary during 3 consecutive days in&#xD;
             the 7 days prior to the Baseline Visit, and subjects must report a minimum of 1&#xD;
             incontinence episode per day or &gt; 4 incontinence episodes over the 3 days as reported&#xD;
             in the 3-day voiding diary.&#xD;
&#xD;
          7. For the Baseline 3-day diary, subjects must be compliant with recording events (i.e.&#xD;
             void, leak or fluid intake) as determined through coordinator interview with the&#xD;
             subject and review of voids and fluid intake reported in the diary compared to normal&#xD;
             daily measurements.&#xD;
&#xD;
        I.4 Pre-menopausal females, ≥18 years of age. Premenopausal is defined as a woman who has&#xD;
        had menstrual cycles over the previous 12 months or who is determined to be premenopausal&#xD;
        by the PI or sub-investigator (e.g. premenopausal woman with hysterectomy).&#xD;
&#xD;
        I.5 Body mass index (BMI) of ≤35 kg/m² at the Screening Visit. I.6 Normal, or abnormal but&#xD;
        not clinically significant (i.e., mild atrophy with rugae present, low grade prolapse),&#xD;
        physical, pelvic and neurologic exam at the Baseline Visit as determined by the&#xD;
        investigator.&#xD;
&#xD;
        I.7 Negative urine pregnancy test at the Baseline and Randomization Visits and subject&#xD;
        agrees to not become pregnant during the study and uses an acceptable form of birth control&#xD;
        started at least 3 months prior to screening (with the exception of double barrier&#xD;
        contraception, where the 3-months required prior to screening does not apply).&#xD;
&#xD;
          1. Examples of acceptable forms of birth control include: abstinence from heterosexual&#xD;
             vaginal intercourse, hysterectomy, bilateral tubal ligation, vasectomy, double barrier&#xD;
             contraception (note that condom and spermicide is not considered double barrier&#xD;
             contraception), intrauterine device or hormonal contraceptive.&#xD;
&#xD;
          2. Rhythm and withdrawal are not considered acceptable forms of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        E.1 Currently breastfeeding or have discontinued breastfeeding fewer than 6 months prior to&#xD;
        screening.&#xD;
&#xD;
        E.2 Undergone other stress urinary incontinence treatment(s), excluding behavioral&#xD;
        modifications started &gt;3 months prior to screening (e.g., Kegel exercises).&#xD;
&#xD;
        E.3 A MESA score of greater than 5 in sum on questions 10 - 12, or greater than 9 in sum on&#xD;
        questions 10 - 15 at the screening visit (see appendix).&#xD;
&#xD;
        E.4 A post void residual measurement of greater than 150 ml as measured with ultrasound or&#xD;
        bladder scanner at the screening visit.&#xD;
&#xD;
        E.5 Greater than 10 voids per day on average as measured with the 3-day diary at Baseline&#xD;
        Visit.&#xD;
&#xD;
        E.6 Greater than 1 nocturia episode per day on average as measured with the 3-day diary at&#xD;
        Baseline Visit.&#xD;
&#xD;
        E.7 Abnormal, clinically significant laboratory results at the Baseline Visit (as&#xD;
        determined by the Investigator) that could impact the subject participation or evaluation&#xD;
        for SUI. Retest is allowed with Sponsor approval.&#xD;
&#xD;
        E.8 Greater than 100 ounces of fluid consumed per day on average as measured with the 3-day&#xD;
        diary at baseline Visit.&#xD;
&#xD;
        E.9 History of, or any current condition, illness, or surgery that might confound the&#xD;
        results of urinary incontinence assessment, including, but not limited to:&#xD;
&#xD;
          1. Prominent (i.e., greater than Stage II pelvic organ prolapse as determined by a POP-Q&#xD;
             evaluation (at Baseline) e.g., cystocele, rectocele&#xD;
&#xD;
          2. Neurological disorders (e.g., multiple sclerosis, Parkinson's disease, fibromyalgia)&#xD;
&#xD;
          3. Recurrent Urinary Tract Infections (UTI)&#xD;
&#xD;
          4. Current Urinary Tract Infection (UTI) as assessed by urine dipstick and associated&#xD;
             urinary tract infection symptoms at the Baseline or Randomization Visit. If the&#xD;
             subject has a UTI at the Baseline or Randomization Visit they may be treated with&#xD;
             antibiotics, at the Investigator's discretion, and return within 7 days after UTI&#xD;
             treatment completion.&#xD;
&#xD;
          5. Vesicoureteral reflux&#xD;
&#xD;
          6. Bladder stones&#xD;
&#xD;
          7. Bladder tumors&#xD;
&#xD;
          8. Interstitial cystitis E.10 Has any implantable electrical device [e.g., implantable&#xD;
             pacemaker, automatic implantable cardioverter-defibrillator (AICD)].&#xD;
&#xD;
        E.11 A rectovaginal septum &lt;2 cm. E.12 Planning on future pregnancies after the Viveve&#xD;
        procedure.&#xD;
&#xD;
        E.13 Medical or immunological condition, including, but not limited to:&#xD;
&#xD;
          1. Uncontrolled cardiovascular, respiratory, neoplastic, infectious, and/or&#xD;
             endocrinological condition that could impact the subject's ability to complete the&#xD;
             trial.&#xD;
&#xD;
          2. Uncontrolled diabetes defined as hemoglobin A1c &gt; 7%&#xD;
&#xD;
          3. Untreated chronic abdominal/pelvic pain disorder [including, but not limited to,&#xD;
             dyspareunia, vaginismus, endometriosis, significant vulvovaginal atrophy (VVA),&#xD;
             genitourinary syndrome of menopause (GSM), irritable bowel syndrome, or Crohn's&#xD;
             disease].&#xD;
&#xD;
          4. Untreated medical condition or medication that, in investigator's opinion, may&#xD;
             interfere with adequate wound healing response (e.g., congenital connective tissue&#xD;
             disease) or the subject's ability to complete the clinical trial requirements.&#xD;
&#xD;
          5. Untreated active malignancy (with the exception of basal cell carcinoma of the skin)&#xD;
             or undergoing treatment (using chemotherapeutic agents, radiation therapy, and/or&#xD;
             cytostatic medications) that may interfere with adequate wound healing response or the&#xD;
             subject's ability to complete the trial.&#xD;
&#xD;
          6. Untreated acute or chronic vaginal or vulvar disorder including, but not limited to,&#xD;
             vulvovaginal atrophy/GSM; pain, including provoked/generalized vulvodynia, vulvar&#xD;
             vestibulitis, dysesthetic vulvodynia, or vulvar dystrophy; current/chronic&#xD;
             papulosquamous vulvar dermatoses (e.g., psoriasis, lichen planus, tinea cruris, lichen&#xD;
             sclerosis, seborrheic dermatitis, contact/irritant dermatitis, lichen simplex,&#xD;
             eczema); bullous dermatoses; systemic diseases with potential involvement of vulva;&#xD;
             genital warts; past/current vaginal or vulvar radiotherapy or brachytherapy.&#xD;
&#xD;
          7. Active genital/pelvic infection (e.g., herpes, gonorrhea, chlamydia) observed on&#xD;
             physical or pelvic exam at Baseline.&#xD;
&#xD;
          8. Active yeast infection. If the subject has an active vaginal yeast infection at the&#xD;
             Baseline or Randomization Visit, they may be treated with an antifungal, at the&#xD;
             Investigator's discretion, and return within 7 days after completion of vaginal yeast&#xD;
             infection treatment.&#xD;
&#xD;
        E.14 Chronic use of anti-inflammatory drugs, including ibuprofen, aspirin, and oral&#xD;
        steroids (excluding aspirin that is taken for cardiovascular prophylaxis).&#xD;
&#xD;
        E.15 Started taking any new medication, including herbal supplements and those taken in&#xD;
        teas that potentially affects urination within 28 days prior to the Screening Visit, or had&#xD;
        a change in the dosage of any medication that potentially affects urination within 28 days&#xD;
        of the Screening Visit. Dosage should not change for the remainder of the study unless&#xD;
        medically necessary.&#xD;
&#xD;
        E.16 Started or changed dose of local vaginal hormones &lt;6 weeks before screening.&#xD;
&#xD;
        E.17 Undergone previous elective surgical or non-invasive procedure(s) in the vaginal canal&#xD;
        (including previous treatment with the Viveve System or any other genital radiofrequency&#xD;
        treatment; injectable bulking agent, cosmetic, laser, surgical, and/or genital enhancement&#xD;
        procedure).&#xD;
&#xD;
        E.18 Participated in another clinical study within 6 months of screening or is not willing&#xD;
        to abstain from participating in other clinical studies for duration of trial.&#xD;
&#xD;
        E.19 Employed by Viveve or participating investigative sites.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric S Rovner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger R Dmochowski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Douglas M Massey, Ph.D.</last_name>
    <phone>720.696.8173</phone>
    <email>dmassey@viveve.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Coastal Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Rowe</last_name>
      <phone>251-414-1984</phone>
      <phone_ext>125</phone_ext>
      <email>pam.rowe@amrllc.com</email>
    </contact>
    <investigator>
      <last_name>Charles F White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urological Associates of Southern Arizona, PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>520-351-5582</phone>
      <email>christinam@uasapc.com</email>
    </contact>
    <investigator>
      <last_name>Susan Kalota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Beach Clinical Trials Services, Inc.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Rodriquez</last_name>
      <phone>562-997-3869</phone>
      <email>longbeachtrials0812@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Suzanne Fussell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emerson Clinical Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Escobedo- Escotto</last_name>
      <phone>202-239-0777</phone>
      <phone_ext>101</phone_ext>
      <email>audrey@ecrinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Kristin McDay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IntimMedicine Specialists</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Barbee</last_name>
      <phone>703-242-6362</phone>
      <email>lbarbee@intimmedicine.com</email>
    </contact>
    <investigator>
      <last_name>James Simon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multi-Specialty Research Associates, Inc</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Miller Sims, LPN, CRC</last_name>
      <phone>386-438-8977</phone>
      <email>robbin@msrainc.com</email>
    </contact>
    <investigator>
      <last_name>Miguel Tepedino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A Premier Medical Research of Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norma Lyn</last_name>
      <phone>386-960-7714</phone>
      <email>drnlyn@apmrofflorida.com</email>
    </contact>
    <investigator>
      <last_name>Luis Pardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Urology Partners</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Seibert</last_name>
      <phone>239-223-4488</phone>
      <email>linda@gulfcoastcta.com</email>
    </contact>
    <investigator>
      <last_name>Osvaldo Padron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leavitt Clinical Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Cortez</last_name>
      <phone>208-502-3039</phone>
      <email>rebecca@drleavitt.net</email>
    </contact>
    <investigator>
      <last_name>Glenn Leavitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan S Baker, RN, MSM</last_name>
      <phone>316-425-6333</phone>
      <email>bryan@cypressmrc.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Integrity, LLC</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacque Nalley</last_name>
      <phone>270-691-1829</phone>
      <email>jacquenalley@drvora.com</email>
    </contact>
    <investigator>
      <last_name>Angela Dawson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Telano</last_name>
      <phone>318-683-0411</phone>
      <email>ktelano@regionalurology.com</email>
    </contact>
    <investigator>
      <last_name>Kevin J Cline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <zip>21117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rayna Bennett-Campbell</last_name>
      <phone>443-231-1203</phone>
      <email>rbennett@chesuro.com</email>
    </contact>
    <investigator>
      <last_name>Laura Giusto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Women's Care, P.A.</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyndsey Gapinski</last_name>
      <phone>651-600-3035</phone>
      <phone_ext>79</phone_ext>
      <email>lgapinski@mnwcare.com</email>
    </contact>
    <investigator>
      <last_name>Melvin Ashford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boeson Research</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellie Bilyeu</last_name>
      <phone>406-763-8833</phone>
      <email>ellie@boesonresearch.com</email>
    </contact>
    <investigator>
      <last_name>Merlin Fausett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adult and Pediatric Urology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>516-746-2190</phone>
      <email>Accumed@aol.com</email>
    </contact>
    <investigator>
      <last_name>Mitchell Efros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Circuit Clinical</name>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>716-919-1130</phone>
      <email>recruitment@circuitclinical.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Constantine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unified Women's Health Care of Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique Carignan</last_name>
      <phone>919-788-4465</phone>
      <email>monique.carignan@unifiedhc.com</email>
    </contact>
    <investigator>
      <last_name>Robert Littleton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UWCR-Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allie Deal</last_name>
      <phone>336-397-3715</phone>
      <email>Alexandra.deal@unifiedhc.com</email>
    </contact>
    <investigator>
      <last_name>Bradley Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center, LLC</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alketa Dobi</last_name>
      <phone>215-884-1700</phone>
      <email>clinicaltrialcenter@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Marvin Kalafer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zandra B Kennedy</last_name>
      <phone>215-805-0410</phone>
      <email>zandra.kennedy@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Lilly Arya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Venus Gynecology, LLC</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Johnson</last_name>
      <phone>843-449-0803</phone>
      <email>tjohnson@venusgyn.com</email>
    </contact>
    <investigator>
      <last_name>Helena Kirkpatrick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advances In Health Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-795-5964</phone>
      <email>AIH@advancesinhealthresearch.com</email>
    </contact>
    <investigator>
      <last_name>Alfred Poindexter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedar Health Research</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-253-8170</phone>
      <email>info@cedarresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jeff Livingston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maximos OB/GYN</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Orsak</last_name>
      <phone>832-632-1333</phone>
      <email>jessica@maximosobgyn.com</email>
    </contact>
    <investigator>
      <last_name>Bassem Maximos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Salas</last_name>
      <phone>210-617-4116</phone>
      <email>Sandra.salas@urologysa.com</email>
    </contact>
    <investigator>
      <last_name>Kurt Meissner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandie Fronzaglio</last_name>
      <phone>757-591-8100</phone>
      <email>mfronz@hrhr-inc.com</email>
    </contact>
    <investigator>
      <last_name>George Freeman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

